Andao Pharmaceutical has completed a Series C financing round exceeding RMB 400 million.

36Kr learned from Yifeng Capital that recently, "Andao Pharmaceutical" announced the completion of a Series C financing round exceeding RMB 400 million. This round of financing was invested by institutions such as Yuanda Industrial Finance (with Huadong Medicine as the main limited partner), Taiping Healthcare Fund, C&D Emerging Investment, Hangzhou Taikun, Zhejiang Province's "4+1" Biomedical and High - end Equipment Industry Fund, Guangzhou Industrial Investment, Guangzhou Development Zone, Kejin Holdings, and Hangzhou Talent Fund. Old shareholders such as Yifeng Capital, Banyan Capital, and Northern Light Venture Capital also participated in the follow - on investment. The funds raised in this round will be mainly used to accelerate the global clinical research of AND017 and AND019, as well as the IND research of the company's in - development small molecule drugs and ADC drugs.